London Genetics, Astrimmune to Develop Biomarkers for Pancreatic Cancer Vaccine | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – London Genetics and Astrimmune today announced a collaboration to identify predictive biomarkers for a pancreatic cancer vaccine being developed by Astrimmune.

The collaboration, being supported with a grant from the UK East Midlands Development Agency, will seek to identify biomarkers predictive of clinical response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.